Assura set for acquisition by private equity consortium

Published 14/05/2025, 16:54
Assura set for acquisition by private equity consortium

LONDON - Assura PLC, a healthcare property developer and investor, is poised to be acquired by Sana Bidco Limited, a company formed by funds advised by Kohlberg Kravis Roberts & Co. L.P. (KKR) and Stonepeak Partners LP. The acquisition, which is recommended by Assura’s board, is to be executed via a scheme of arrangement as per the Companies Act 2006.

The scheme document detailing the terms and conditions of the bid has been published and dispatched to Assura shareholders, who are scheduled to vote on the acquisition at a court meeting on June 5, 2025, followed immediately by a general meeting. Approval from at least 75% in value of the voting shareholders is required at the court meeting, in addition to a majority at the general meeting.

Assura’s directors, advised by financial firm Lazard (NYSE:LAZ), have endorsed the offer, considering it fair and reasonable. They have unanimously recommended that shareholders approve the scheme, with directors having already committed to vote in favor of the acquisition in respect of their own shareholdings.

The acquisition is subject to the satisfaction or waiver of other conditions outlined in the scheme document. Shareholders have been urged to vote, as a significant turnout is needed for the court to sanction the scheme. The document also includes an indicative timetable for the acquisition process, which is expected to be completed by the third quarter of 2025.

This strategic move comes as private equity firms continue to show interest in the healthcare sector, with Assura’s portfolio of primary care facilities being a valuable asset. The acquisition is set to expand the consortium’s footprint in the healthcare real estate market.

Assura shareholders are advised to review the scheme document and accompanying proxy forms carefully before casting their votes. The information for this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.